# RO APM: What You Need to Know Initial Overview

Elekta Health Policy and Government Affairs Team July 19, 2019



#### **Presentation Overview**

Proposed RO APM: What You Need to Know

- Model History and Overview
- How the Model Works
- RO APM Summary and Next Steps



# Model History and Overview


Proposed RO APM

#### Role of Medicare in US Health Care

Medicare provides health insurance for most adults age 65 and older

Although Medicare only insures a fraction of the US population, Medicare payment and coverage policies set the standard for other insurers

#### Health insurance Coverage in US, 2017








#### Shift from Volume to Value


**Evolving Medicare payment landscape** 



Opportunities for efficient and high value treatments, such as radiation therapy, exist within this payment landscape shift



# **RO APM Is Implemented by the CMS Innovation Center**





- The CMS Innovation Center was established by Section 115A of the Social Security Act under the Affordable Care Act
- The CMS Innovation Center tests new payment models, including Advanced Alternative Payment Models



#### **RO APM Timeline**


#### PAMPA initiated RO APM process







# Timing for Implementation of RO APM




Medicare payment rules for fee for service radiation therapy services provided in outpatient hospitals and freestanding facilities will follow a similar timeline



# RO APM Will Be Implemented Under the CMS Innovation Center

RO APM will be run for up to **five** years, culminating on December 31, 2024 Target Medicare program savings of 3% If program meets savings goals, potential for program-wide implementation




APM: Alternative Payment Model; MACRA: Medicare Access and CHIP Reauthorization Act; MIPS: Merit Based Incentive Payments System Focus where it matters.



#### What Is and Is Not Included in the Bundle

Included in Bundle




#### **Radiation Therapy Services**

Treatment Planning
Treatment
Management

Technical Preparation
and Special Services
Treatment
Delivery

Not included in the Bundle, Paid FFS



**Evaluation & Management** 

Certain Imaging Procedures

FFS: Fee for Service; HDR: High Dose Rate; IGRT: Image Guided Radiation Therapy; IORT: Intraoperative Radiation Therapy; LDR: Low Dose Rate; SBRT: Stereotactic Body Radiation Therapy; SRS: Stereotactic Radiosurgery







<sup>\*</sup>CMS is considering excluding Proton Beam Therapy from the bundle when the beneficiary is participating in a federally-funded, multi-institution randomized controlled clinical trial

# **How the Model Works Model Mechanics**

## We Will Be Living Under Two Payment Systems

Fee for Service Medicare and RO APM will coexist from 2020-2025







Sites are on one side of the wall or the other


40% of Episodes



# **Determination of Sites in Mandatory Model**

#### CMS will use CBSAs to determine site inclusion

- CMS will identify randomly selected Core Based Statistical Areas (CBSAs) for participation in the model
  - 40% of radiation episodes will be included in participating CBSAs
- CBSAs included in the model will be released with the final rule, expected in early November 2019
- Certain sites are will be excluded from the model, including:
  - Sites in Maryland and Vermont (due to existing all payer models)
  - Critical access hospital or those with Pennsylvania rural health designation
  - PPS-exempt cancer hospitals
  - Ambulatory surgical centers (ASCs)



Source: Core Based Statistical Areas, US Census Bureau, Public Domain



Focus where it matters.



## **Site Neutral Payment**

#### Both hospital outpatient and freestanding sites will receive same payment amount

# Current FFS Payment Payment Depends on Site of Service

(60% of Episodes)

#### Medicare Physician Fee Schedule (MPFS)

Physician's Office



Payment rate includes: professional and technical components

Freestanding Centers



Payment rate includes: professional and technical components

Hospital Outpatient:
Physician Component



Payment rate includes: professional component

Outpatient
Prospective
Payment System
(OPPS)

**Hospital Outpatient:** Facility Component



Payment rate includes: technical component

# Proposed RO APM Site Neutral



**Freestanding** 

Technical Component (TC) +
Professional Component (PC)
or
Dual Participant



**Hospital Outpatient** 


Technical Component (TC) + Professional Component (PC)

The RO APM is site neutral, meaning there is a common payment amount for services regardless of where they are furnished



## Cancer Types Included in the RO APM

#### Inclusive of commonly treated cancer types



Body represents male and female indications and is intended for illustration purposes only.

Focus where it matters.

CNS: Central Nervous System; GI: Gastrointestinal; ICD-10-CM: International Classification of Diseases, Tenth Revision, Clinical Modification

CMS proposes to include 17 cancer types in the model that will be identified with ICD-10-CM diagnosis codes

|                      | ICD-9 AND ICD-10 CODES                  |                        |  |
|----------------------|---|------------------------|--|
|                      |   |                        |  |
| Cancer Type          | ICD-9 Codes                             | ICD-10 Codes           |  |
| nal Cancer           | 154.2x, 154.3x                          | C21.xx                 |  |
| ladder Cancer        | 188.xx                                  | C67.xx                 |  |
| one Metastases       | 198.5x                                  | C79.5x                 |  |
| rain Metastases      | 198.3x                                  | C79.3x                 |  |
| reast Cancer         | 174.xx, 175.xx, 233.0x                  | C50.xx, D05.xx         |  |
| ervical Cancer       | 180.xx                                  | C53 xx                 |  |
| NS Tumors            | 191.xx, 192.0x, 192.1x, 192.2x, 192.3x, | C70.xx, C71.xx, C72.xx |  |
|                      | 192.8x, 192.9x                          | , , , , , ,            |  |
| olorectal Cancer     | 153.xx, 154.0x, 154.1x, 154.8x          | C18.xx, C19.xx, C20.xx |  |
| Head and Neck Cancer | 140.xx, 141.0x, 141.1x, 141.2x, 141.3x, | C00.xx, C01.xx, C02.xx |  |
|                      | 141.4x, 141.5x, 141.6x, 141.8x, 141.9x, | C03.xx, C04.xx, C05.xx |  |
|                      | 142.0x, 142.1x, 142.2x, 142.8x, 142.9x, | C06.xx, C07.xx, C08.xx |  |
|                      | 143.xx, 144.xx, 145.0x, 145.1x, 145.2x, | C09.xx, C10.xx, C11.xx |  |
|                      | 145.3x, 145.4x, 145.5x, 145.6x, 145.8x, | C12.xx, C13.xx, C14.xx |  |
|                      | 145.9x, 146.0x, 146.1x, 146.2x, 146.3x, | C30.xx, C31.xx, C32.xx |  |
|                      | 146.4x, 146.5x, 146.6x, 146.7x, 146.8x, | C76.0x                 |  |
|                      | 146.9x                                  |                        |  |
|                      | 147.xx, 148.0x, 148.1x, 148.2x, 148.3x, |                        |  |
|                      | 148.8x, 148.9x, 149.xx, 160.0x, 160.1x, |                        |  |
|                      | 160.2x, 160.3x, 160.4x, 160.5x, 160.8x, |                        |  |
|                      | 160.9x, 161.xx, 195.0x                  |                        |  |
| lnev Cancer          | 189.0x                                  | C64.xx                 |  |
| ver Cancer           | 155.xx, 156.0x, 156.1x, 156.2x, 156.8x, | C22.xx, C23.xx, C24.xx |  |
|                      | 156.9x                                  | ,,,                    |  |
| ng Cancer            | 162.0x, 162.2x, 162.3x, 162.4x, 162.5x, | C33.xx, C34.xx, C39.xx |  |
|                      | 162.8x, 162.9x, 165.xx                  | C45.xx                 |  |
| mphoma               | 202.80, 202.81, 202.82, 202.83, 202.84, | C81.xx, C82.xx, C83.xx |  |
| ., <b></b>           | 202.85, 202.86, 202.87, 202.88, 203.80, | C84.xx, C85.xx, C86.xx |  |
|                      | 203.82, 200.0x, 200.1x, 200.2x, 200.3x, | C88.xx. C91.4x         |  |
|                      | 200.4x, 200.5x, 200.6x, 200.7x, 200.8x, | ,                      |  |
|                      | 201.xx, 202.0x, 202.1x, 202.2x, 202.4x, |                        |  |
|                      | 202.7x, 273.3x                          |                        |  |
| ncreatic Cancer      | 157.xx                                  | C25.xx                 |  |
| rostate Cancer       | 185.xx                                  | C61.xx                 |  |
| pper GI Cancer       | 150.xx, 151.xx, 152.xx                  | C15.xx, C16.xx, C17.xx |  |
| terine Cancer        | 179.xx. 182.xx                          | C54.xx, C55.xx         |  |



### **RO APM Participant National Base Rates**

#### Rates per disease site will be adjusted


- CMS developed national base rates using HOPD cost data from 2015-2017
- These base rates will be adjusted based on:
  - Annual updates
  - Practice historical experience
  - Practice geography
  - Withholds
  - Discounts
  - Beneficiary Cost Sharing
  - Sequester

| Cancer Type                 | Professional | Technical | Global/Dual |
|-----------------------------|--------------|-----------|-------------|
| <b>Anal Cancer</b>          | \$2,968      | \$16,006  | \$18,974    |
| <b>Bladder Cancer</b>       | \$2,637      | \$12,556  | \$15,193    |
| <b>Bone Metastases</b>      | \$1,372      | \$5,568   | \$6,940     |
| <b>Brain Metastases</b>     | \$1,566      | \$9,217   | \$10,783    |
| <b>Breast Cancer</b>        | \$2,074      | \$9,740   | \$11,814    |
| <b>Cervical Cancer</b>      | \$3,779      | \$16,955  | \$20,734    |
| <b>CNS Tumors</b>           | \$2,463      | \$14,193  | \$16,656    |
| <b>Colorectal Cancer</b>    | \$2,369      | \$11,589  | \$13,958    |
| <b>Head and Neck Cancer</b> | \$2,947      | \$16,708  | \$19,655    |
| <b>Kidney Cancer</b>        | \$1,550      | \$7,656   | \$9,206     |
| Liver Cancer                | \$1,515      | \$14,650  | \$16,165    |
| Lung Cancer                 | \$2,155      | \$11,451  | \$13,606    |
| Lymphoma                    | \$1,662      | \$7,444   | \$9,106     |
| Pancreatic Cancer           | \$2,380      | \$13,070  | \$15,450    |
| <b>Prostate Cancer</b>      | \$3,228      | \$19,852  | \$23,080    |
| <b>Upper GI Cancer</b>      | \$2,500      | \$12,619  | \$15,119    |
| <b>Uterine Cancer</b>       | \$2,376      | \$11,221  | \$13,597    |

HOPD: Hospital Outpatient Department



# **Participant Specific Payment Calculation**



\*-2% for PYs 1 and 2, -3% for PYs 3, 4, and 5

GPCI: Geographic Practice Cost Index; PC: Professional Component; PY: Performance Year; TC: Technical Component


Focus where it matters.



**Per Patient Rate** 

# Payment Mechanism —Technical and Professional Components

Start of Episode



50% of Episode-Based PC Payment \$

50% of Episode-Based TC Payment \$

**End of Episode** 

Model Specific HCPCS Code



**EOE Modifier** 

28 days of the treatment planning code


50% of Episode-Based PC Payment \$

50% of Episode-Based TC Payment Sites will be required to bill for all services required, in addition to the codes that trigger payment under the bundle

EOE: End of Episode; HCPCS: Healthcare Common Procedure Coding System; SOE: Start of Episode **Focus where it matters.** 



# Bundled payment will cover all specified RO services provided in a 90-day episode





# Quality Measure, Patient Survey, and Clinical Data Reporting

Professional and dual participants will be required to report 4 quality measures

Preventative Care and Screening: Screening for Depression and Follow-Up Plan


Advance Care Plan

Oncology: Medical and Radiation - Plan of Care for Pain

Treatment Summary
Communication –
Radiation Oncology


Technical and dual participants will be required to submit patient survey data in PYs 3-5

CAHPS Cancer Survey for Radiation



CAHPS: Consumer Assessment of Healthcare Providers and Systems





## **Proposed RO APM Summary**

#### **Key Takeaways**

The RO APM model fundamentally changes the way CMS pays for radiation oncology services by replacing FFS payments with a 90 day episode of care bundled payment

- APM Details: The RO APM bundle payment is site neutral, technology agnostic, and unique for 17 different disease sites (skin cancer and benign neoplasms are notable exclusions)
- Participation: Participation will be mandatory for sites in selected CBSAs and total participation will represent 40% of RO episodes under FFS Medicare. A full list of participating sites will be released with the final rule in November 2019
- Payment Mechanism: The prospective national base rates are set using hospital outpatient data from 2015-2017; a multi-step process will adjust the payment levels per disease site and is site neutral, meaning the rate setting does not differentiate based on setting of care
- Timing: Earliest implementation is scheduled for January 1, 2020; CMS is also considering an April 1, 2020 start date
- Changes: All details of the RO APM are subject to change based on final rulemaking; CMS will may make
  edits to the RO APM based on stakeholder input
- Other Considerations: While there are no specific provisions for new technology or advanced technology in the RO APM, CMS left the door open for model adaptations for future innovations



## **Next Steps**

#### **Education and Advocacy Efforts**

- Elekta is fully engaged on this issue
  - Advocacy efforts are underway from Elekta and members of the RT community to promote fair and adequate reimbursement levels and policy considerations under this proposed RO APM
- Additional webinars and educational opportunities on impact of the RO APM are in the planning stage—stay tuned for more details on dates and time
- The RO APM will be addressed at the Elekta User Meeting at ASTRO

Save the Date! Elekta User Meeting September 14, 2019







# **Thank You**

#### Please contact us:

Elekta.Reimbursement@Elekta.com

Focus where it matters.

# Questions?

Ask us, we may know